US 12,109,206 B2
Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders
Eric A. Marcotulli, New York, NY (US); Daniel A. Alminana, New York, NY (US); and Paul M. Bowen, Newton, MA (US)
Assigned to Elysium Health, Inc., New York, NY (US)
Filed by Elysium Health, Inc., New York, NY (US)
Filed on Jul. 25, 2022, as Appl. No. 17/872,575.
Application 17/872,575 is a continuation of application No. 15/735,066, granted, now 11,426,398, previously published as PCT/US2016/019653, filed on Feb. 25, 2016.
Claims priority of provisional application 62/173,733, filed on Jun. 10, 2015.
Prior Publication US 2022/0362233 A1, Nov. 17, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 8/368 (2006.01); A61K 8/67 (2006.01); A61K 9/00 (2006.01); A61K 9/48 (2006.01); A61K 31/09 (2006.01); A61K 31/455 (2006.01); A61K 31/706 (2006.01); A61P 17/00 (2006.01); A61Q 19/00 (2006.01)
CPC A61K 31/455 (2013.01) [A61K 8/368 (2013.01); A61K 8/675 (2013.01); A61K 9/0053 (2013.01); A61K 9/4866 (2013.01); A61K 31/09 (2013.01); A61K 31/706 (2013.01); A61P 17/00 (2018.01); A61Q 19/004 (2013.01); A61K 2300/00 (2013.01)] 6 Claims
 
1. A method of treating sunburn in a patient in need thereof comprising orally administering a combination of a therapeutically effective amount of nicotinamide riboside and a therapeutically effective amount of pterostilbene, wherein the therapeutically effective amount of nicotinamide riboside is 250 mg per day, the therapeutically effective amount of pterostilbene is 50 mg per day.